company background image
1513 logo

Livzon Pharmaceutical Group SEHK:1513 Stock Report

Last Price

HK$26.55

Market Cap

HK$30.7b

7D

1.9%

1Y

-6.2%

Updated

16 May, 2025

Data

Company Financials +

Livzon Pharmaceutical Group Inc.

SEHK:1513 Stock Report

Market Cap: HK$30.7b

1513 Stock Overview

Researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People’s Republic of China. More details

1513 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth1/6
Past Performance4/6
Financial Health5/6
Dividends4/6

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Livzon Pharmaceutical Group Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Livzon Pharmaceutical Group
Historical stock prices
Current Share PriceCN¥26.55
52 Week HighCN¥34.00
52 Week LowCN¥23.10
Beta0.42
1 Month Change3.31%
3 Month Change1.14%
1 Year Change-6.18%
3 Year Change3.51%
5 Year Change-11.79%
Change since IPO48.69%

Recent News & Updates

Recent updates

Shareholder Returns

1513HK PharmaceuticalsHK Market
7D1.9%-1.0%3.0%
1Y-6.2%6.2%12.2%

Return vs Industry: 1513 underperformed the Hong Kong Pharmaceuticals industry which returned 6.2% over the past year.

Return vs Market: 1513 underperformed the Hong Kong Market which returned 12.2% over the past year.

Price Volatility

Is 1513's price volatile compared to industry and market?
1513 volatility
1513 Average Weekly Movement4.0%
Pharmaceuticals Industry Average Movement7.4%
Market Average Movement8.0%
10% most volatile stocks in HK Market15.4%
10% least volatile stocks in HK Market4.2%

Stable Share Price: 1513 has not had significant price volatility in the past 3 months compared to the Hong Kong market.

Volatility Over Time: 1513's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19859,067Yanggang Tangwww.livzon.com.cn

Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People’s Republic of China. The company offers drug preparation products, including Ilaprazole enteric coated tablets to treat duodenal ulcers and reflux esophagitis; Laprazole sodium for injection to treat peptic ulcer hemorrhage; Leuprorelin Acetate Microspheres for injection to treat endometriosis, hysteromyoma, premenopausal breast and prostate cancer, and central precocious puberty; and Urofollitropin for injection to treat anovulation and sufferers. It also provides Perospirone hydrochloride tablets to treat schizophrenia; Shenqi Fuzheng Injection to treat weakness and tiredness, lassitude, spontaneous sweating, and vertigo, as well as for treating lung and stomach cancer; anti-viral granules used for clearing heat, eliminating dampness, cooling blood, and detoxifying to treat upper respiratory tract infection and influenza; Tocilizumab injection to treat rheumatoid arthritis; and Recombinant SARSCoV-2 fusion protein vaccine used to prevent diseases caused by SARS-CoV-2 infection.

Livzon Pharmaceutical Group Inc. Fundamentals Summary

How do Livzon Pharmaceutical Group's earnings and revenue compare to its market cap?
1513 fundamental statistics
Market capHK$30.70b
Earnings (TTM)HK$2.27b
Revenue (TTM)HK$12.74b

15.1x

P/E Ratio

2.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1513 income statement (TTM)
RevenueCN¥11.75b
Cost of RevenueCN¥4.22b
Gross ProfitCN¥7.53b
Other ExpensesCN¥5.44b
EarningsCN¥2.09b

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)2.34
Gross Margin64.11%
Net Profit Margin17.79%
Debt/Equity Ratio25.0%

How did 1513 perform over the long term?

See historical performance and comparison

Dividends

3.1%

Current Dividend Yield

48%

Payout Ratio

Does 1513 pay a reliable dividends?

See 1513 dividend history and benchmarks
When do you need to buy 1513 by to receive an upcoming dividend?
Livzon Pharmaceutical Group dividend dates
Ex Dividend DateJun 13 2025
Dividend Pay DateJul 11 2025
Days until Ex dividend27 days
Days until Dividend pay date55 days

Does 1513 pay a reliable dividends?

See 1513 dividend history and benchmarks

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/16 19:02
End of Day Share Price 2025/05/16 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Livzon Pharmaceutical Group Inc. is covered by 24 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ling ZhangBNP Paribas Securities (Asia)
Helena QiuCCB International Securities Limited
Shuchang LiuChangjiang Securities Co. LTD.